1XT.F XINTELA AB
- Market cap
- EUR 517K
- P/E
- -
- P/B
- 9.95x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1XT.F undervalued?
Graham numberThe Graham number of XINTELA AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
XINTELA AB fundamental analysis
No fundamental analysis for XINTELA AB yet.
XINTELA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About XINTELA AB
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is …
Full company profileXINTELA AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
XINTELA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 78.0K | 4.22M | 2.28M | 3.52M |
| Gross Profit | 0.00 | 0.00 | 78.0K | 4.22M | 2.28M | 3.52M |
| Operating Income | -60.1M | -69.1M | -57.2M | -39.4M | -46.7M | -41.8M |
| EBITDA | - | -64.8M | -53.5M | -38.9M | -46.1M | -41.3M |
| Net Income | -59.6M | -66.2M | -54.1M | -39.2M | -48.6M | -43.1M |
| EPS | -0.39 | -0.21 | -0.09 | -0.06 | -0.06 | -0.05 |
| Balance Sheet | ||||||
| Total Assets | 27.0M | 24.5M | 18.4M | 24.8M | 29.0M | 35.1M |
| Total Liabilities | 24.5M | 18.7M | 14.0M | 30.7M | 34.3M | 62.3M |
| Shareholders' Equity | 2.51M | 5.78M | 4.38M | -5.95M | -5.27M | -27.2M |
| Cash & Short-term Investments | 11.1M | 8.34M | 7.81M | 16.7M | 23.2M | 30.7M |
| Cash Flow | ||||||
| Operating Cash Flow | -42.9M | -73.1M | -53.1M | -40.7M | -41.6M | -44.1M |
| Capital Expenditure | 1.26M | 111K | 104K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -44.1M | -73.1M | -53.2M | -40.7M | -41.6M | -44.1M |
| Ratios | ||||||
| ROE | -2,376.3% | -1,146.2% | -1,234.8% | - | - | - |
| ROA | -220.9% | -270.1% | -294.0% | -158.0% | -167.3% | -122.8% |
| Net Profit Margin | - | - | -69,337.2% | -929.8% | -2,128.1% | -1,224.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
XINTELA AB dividends
XINTELA AB has not paid dividends in the last 5 fiscal years.
Who owns XINTELA AB
- Insiders 7.03%
- Institutions 65.54%
- Public & others 27.43%
- Shares outstanding 861M
- Free float 403M
XINTELA AB company profile
- Company name
- XINTELA AB
- Ticker
- 1XT.F
- ISIN
- SE0007756903
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- Medicon Village, Lund, Sweden, 223 81
- Phone
- 46 4 62 75 65 00
- Website
- xintela.se
About XINTELA AB
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. It has an agreement with Region Östergötland for GMP process development of cell therapy for burn patients. Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
XINTELA AB management
4- Dr. Evy Lundgren-Åkerlund Assoc.Prof, BSc, Ph.D.Chief Executive Officer · born 1957
- Mr. Gunnar TelhammarCFO & Finance Director · born 1961
- Ms. Lucienne VonkChief Scientific Officer
- Mr. Stijn Heessen Ph.D.Head of Business Development